Advisors Capital Management LLC Has $38.75 Million Stock Position in Pfizer Inc. $PFE

Advisors Capital Management LLC lifted its position in shares of Pfizer Inc. (NYSE:PFE) by 53.9% in the first quarter, according to its most recent disclosure with the SEC. The institutional investor owned 1,529,067 shares of the biopharmaceutical company’s stock after buying an additional 535,385 shares during the quarter. Advisors Capital Management LLC’s holdings in Pfizer were worth $38,747,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors also recently modified their holdings of the company. William B. Walkup & Associates Inc. raised its stake in Pfizer by 1.2% in the fourth quarter. William B. Walkup & Associates Inc. now owns 39,368 shares of the biopharmaceutical company’s stock valued at $1,044,000 after purchasing an additional 454 shares in the last quarter. Members Trust Co raised its stake in Pfizer by 2.1% in the first quarter. Members Trust Co now owns 23,175 shares of the biopharmaceutical company’s stock valued at $587,000 after purchasing an additional 467 shares in the last quarter. Sutton Place Investors LLC raised its stake in Pfizer by 5.6% in the first quarter. Sutton Place Investors LLC now owns 8,833 shares of the biopharmaceutical company’s stock valued at $224,000 after purchasing an additional 472 shares in the last quarter. MSH Capital Advisors LLC raised its stake in Pfizer by 1.4% in the first quarter. MSH Capital Advisors LLC now owns 34,585 shares of the biopharmaceutical company’s stock valued at $876,000 after purchasing an additional 485 shares in the last quarter. Finally, Signature Estate & Investment Advisors LLC raised its stake in Pfizer by 2.6% during the first quarter. Signature Estate & Investment Advisors LLC now owns 19,254 shares of the biopharmaceutical company’s stock worth $488,000 after acquiring an additional 486 shares in the last quarter. Institutional investors and hedge funds own 68.36% of the company’s stock.

Analyst Upgrades and Downgrades

PFE has been the subject of several research analyst reports. Citigroup boosted their target price on Pfizer from $25.00 to $26.00 and gave the stock a “neutral” rating in a research note on Wednesday, August 6th. HSBC lowered their target price on Pfizer from $27.00 to $26.00 and set a “buy” rating for the company in a research note on Monday, May 19th. Berenberg Bank lowered their target price on Pfizer from $28.00 to $25.00 and set a “hold” rating for the company in a research note on Thursday, May 29th. Jefferies Financial Group upped their price objective on Pfizer from $32.00 to $33.00 and gave the company a “buy” rating in a research note on Wednesday, May 21st. Finally, Morgan Stanley upped their price objective on Pfizer from $32.00 to $33.00 and gave the company an “equal weight” rating in a research note on Wednesday, August 6th. Two investment analysts have rated the stock with a Strong Buy rating, four have given a Buy rating, eleven have assigned a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, Pfizer currently has a consensus rating of “Hold” and an average price target of $28.12.

Pfizer Stock Performance

Shares of PFE stock opened at $24.59 on Thursday. The stock has a market capitalization of $139.79 billion, a PE ratio of 13.08, a PEG ratio of 0.88 and a beta of 0.55. Pfizer Inc. has a one year low of $20.92 and a one year high of $30.43. The business’s 50 day simple moving average is $24.83 and its 200 day simple moving average is $24.33. The company has a debt-to-equity ratio of 0.65, a current ratio of 1.16 and a quick ratio of 0.85.

Pfizer (NYSE:PFE) last posted its quarterly earnings results on Tuesday, August 5th. The biopharmaceutical company reported $0.78 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.58 by $0.20. The firm had revenue of $14.65 billion for the quarter, compared to analysts’ expectations of $13.43 billion. Pfizer had a return on equity of 21.42% and a net margin of 16.84%.The company’s revenue for the quarter was up 10.3% compared to the same quarter last year. During the same period in the prior year, the business earned $0.60 EPS. Pfizer has set its FY 2025 guidance at 2.900-3.100 EPS. As a group, research analysts forecast that Pfizer Inc. will post 2.95 earnings per share for the current year.

Pfizer Dividend Announcement

The firm also recently declared a quarterly dividend, which was paid on Tuesday, September 2nd. Shareholders of record on Friday, July 25th were issued a dividend of $0.43 per share. This represents a $1.72 dividend on an annualized basis and a dividend yield of 7.0%. The ex-dividend date was Friday, July 25th. Pfizer’s dividend payout ratio is presently 91.49%.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.